Skip to main content


Long-Term Rituximab in ANCA-Associated Vasculitis

Aug 06, 2020

The Annals of Internal Medicine reports that biannual rituximab infusions over 18 months was effective at maintaining remission in patients with antineutrophil cytoplasmic antibody–associated vasculitis (AAV).

Read Article

Methotrexate Not Associated with Interstitial Lung Disease

Aug 05, 2020

A case-controlled study shows that methotrexate (MTX) use in rheumatoid arthritis (RA) is not associated with interstitial lung disease (ILD) according to a report in the European Respiratory Journal.

Researchers examined the associatioin by comparing 410 RA patients with

Read Article

Uric Acid Targeting in Gout Management

Jul 31, 2020

A study from 2 gout clinics implementing different treatment strategies has shown that a treatment strategy that aims to strictly achieve low uric acid (UA) results in a higher a rate of targetd serum UA lowering and less gout flares.

Two gout clinics with 212 newly diagnosed gout

Read Article

Methotrexate Improves Pegloticase Efficacy and Tolerability

Jul 29, 2020

The efficacy of intravenous pegloticase (PEG) therapy in gout can be limited by its toxicity, but when coadministered with weekly methotrexate, higher response rates and less toxicity was observed.

In published gout clinical trials, the PEG responder rate was 42%. Strategies to limit 

Read Article

SEMIRA Study: Best to Continue Low Dose Steroids in RA

Jul 28, 2020

The SEMIRA trial studied the  tapering vs continuing oral glucocorticoids in rheumatoid arthritis (RA) patients who achieved a low disease activity state (with tocilizumab) were more likely to show safety and better disease control with continuing steroids - even though two-thirds of patients

Read Article

RheumNow Podcast – COVID-19 Responds to Steroids (7.24.20)

Jul 24, 2020

Dr. Jack Cush reviews the News and Journal Reports from the past week on

Read Article

Steroids and Tocilizumab in Cytokine Storm Syndrome

Jul 21, 2020

A recent study from the Netherlands has shown that patients with severe COVID-19-associated cytokine storm syndrome (CSS)  with high dose steroids and tocilizumab had a faster recovery, less need for invasive mechanical ventilation and fewer deaths when compared to CSS patients receiving

Read Article

RECOVERY Trial: Dexamethasone in COVID-19

Jul 20, 2020

Inflammatory events following infection with SARS-CoV-2 can often worsen the morbid or mortal outcomes with COVID, yet it has been unclear if glucocorticoids may modulate inflammation-mediated damage and lung injury.  The RECOVERY trial reports that dexamethasone (DEX) use lowered 28-day

Read Article
RheumNow Podcast is Up! Listen to Fauci! Watch it here>> or Listen to the Podcast>>

Dr. John Cush RheumNow ( View Tweet)

Jul 17, 2020

RheumNow Podcast – LTF – Listen to Fauci (7.17.20)

Jul 17, 2020

Dr. Jack Cush reviews the news, tweets and journal articles from the past week on RheumNow. Let's dig into this week's 14 highlights.

Read Article

2020 ACR Gout Management Guideline

Jul 03, 2020

In May, the American College of Rheumatology (ACR) released the"2020 Guideline for the Management of Gout"reflecting new clinical evidence since the last guideline published in 2012.

The guideline puts forth 42 recommendations, including 16 strong recommendations, based in 52 PICO

Read Article

CV Risks Raised in Myopathies

Jul 02, 2020

Patients with the idiopathic inflammatory myopathies (IIMs) dermatomyositis and polymyositis are at increased risk for cardiovascular events, with risks similar to what has been documented for rheumatoid arthritis (RA), during the first 5 years after diagnosis, U.K. researchers reported.

Read Article

COVID's Multisystem Inflammatory Syndrome in Children

Jun 30, 2020

Two recent reports further characterize the newly described, Kawasaki-like,  syndrome affecting children with COVID-19 infections.

The NEJM describes the childhood syndrome as having Kawasaki’s disease, fever, toxic shock syndrome, acute abdominal conditions, and encephalopathy; hence the label

Read Article

ACR Outlines Best Practices for Kids With MIS-C

Jun 25, 2020

Multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19 infection has both similarities and differences with Kawasaki disease, and requires distinct clinical management, according to draft guidance from the American College of Rheumatology (ACR).

Age, symptoms,

Read Article

Voclosporin Beats Standard of Care in Lupus Nephritis

Jun 17, 2020

The high potency calcineurin inhibitor voclosporin plus standard of care was superior to standard of care alone in a phase III study of lupus nephritis known as AURORA.

Read Article

Canakinumab First FDA-Approved Therapy for Adult-Onset Still's Disease

Jun 17, 2020

Yesterday, the FDA approved canakinumab (Ilaris) as treatment for adult-onset Still's disease (AOSD), the first ever FDA approved drug for AOSD.

Canakinumab, an interleukin-1 inhibitor, was FDA approved in 2013 for use children (aged 2 years and older) with systemic juvenile idiopathic

Read Article

Dexamethasone Reduces Mortality in Severe COVID

Jun 16, 2020

Preliminary results released today shows dexamethasone (DEX), given to hospitalized, severly ill, COVID-19 patients, is capable of reducing mortality rates by one-third, with researchers calling this a “major breakthrough” in coronavirus management.

The results stem from a UK trial, called the

Read Article

Atherosclerotic Events on the Decline in SLE

Jun 15, 2020

The prevalence of atherosclerotic vascular events among patients with systemic lupus erythematosus (SLE) today is considerably lower than in the past, analysis of multicenter data found.

Among patients enrolled in an inception cohort from 1999 to 2017, only 3.6% of patients had an

Read Article

Virtual EULAR 2020 Round Up

Jun 12, 2020

In this week's podcast, Drs. Artie Kavanaugh and Jack Cush present highlights from the virtual EULAR2020 meeting held June 3-6, 2020. Featured reports include the SELECT-CHOICE study, the EXCEED trial, Avacopan in AAV, BeST mortality outcomes, BLISS-LN study, biosimilars and tofa in systemic

Read Article

Day 3 - Top 5 from EULAR 2020

Jun 10, 2020

These were my top abstracts from Thursday, 4th of June at EULAR 2020:

Read Article

EULAR and ACR COVID19 Guidelines: Similarities Provide Reassurance

Jun 05, 2020

In difficult times, it's reassuring to reflect on the similarities that bring us together. In the case of the EULAR and ACR COVID19 guidelines as discussed at #EULAR2020 by Drs. Mikuls and Landewe, the recommendations from both panels proved to be reassuring with a hint of "we are flying

Read Article

First Look at COVID-19 Global Rheumatology Alliance Registry

Jun 01, 2020

Gianfresco et al have published the first peer-reviewed analysis of COVID-19 infected, rheumatic disease patients entered into the Rheumatology Global Alliance registry; showing that a) rheumatic disease patient can be infected with COVID-19, b) that DMARD and biologic use has no apparent effect

Read Article

RheumNow Podcast - Rheumatic Patients with COVID (5.29.20)

May 29, 2020

Dr. Jack Cush reviews the news and journal articles from the past week on

Read Article

TNR Grand Rounds - Cytokine Storm Syndromes

May 27, 2020

This week's Tuesday Nite Rheumatology featured Dr Randy Cron from the University of Alabama - Birmingham as he spoke and took questions on the immunology, immunopathogenesis and treatment of Cytokine Storm Syndrome, especially as they relate to COVID-19 and rheumatic disease patients. The

Read Article

RheumNow Podcast - COVID Kids and Men (5.15.20)

May 15, 2020

Dr. Jack Cush reviews the news and journal articles from the past week on

Read Article